ICI 182,780

A cell-permeable estradiol derivative that acts as an estrogen antagonist and down-regulates estrogen receptors without affecting estrogen receptor-mediated progesterone receptor expression. Hence, it lacks estrogen agonist activity. Shown to be more effective than tamoxifen in reducing estrogen receptors in breast tumor cells. Suppresses the growth of MCF-7 xenografts in mice for twice as long as tamoxifen and delays tumor growth.

Please note that the molecular weight for this compound is batch-specific due to variable water content.

A cell-permeable estradiol derivative that acts as an estrogen antagonist and down-regulates estrogen receptors without affecting estrogen receptor-mediated progesterone receptor expression. Hence, it lacks estrogen agonist activity. Shown to be more effective than tamoxifen in reducing estrogen receptors in breast tumor cells. Suppresses the growth of MCF-7 xenografts in mice for twice as long as tamoxifen and delays tumor growth.



Please note that the molecular weight for this compound is batch-specific due to variable water content.

A cell-permeable estrogen antagonist. More effective than tamoxifen in reducing estrogen receptors in breast tumor cells.

Cell permeable: yes

Primary Target
ER

Secondary Target
GPR30

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Wakeling, A. E., et al. 1991. Cancer Res.51, 3867.
Dauvois, S., et al. 1993. J. Cell. Sci.106, 1377.
Howell, A., et al. 1995. The Lancet.8941, 29.
Robertson, J.F., et al. 2001. J. Steroid Biochem. Mol Biol.79, 209.

Sold with the permission of AstraZeneca UK. Limited for research purposes only.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany